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Abstract
Background The administration of adjuvant chemotherapy
for rectal cancer patients with ypN0 is controversial. The
purposes of this study were to evaluate the role of adjuvant
chemotherapy in ypN0 patients and to optimize its use for
these patients.
Methods We performed a retrospective study of 160 rectal
cancer patients who had the final pathology of ypN0 between
March 2003 and November 2010. Overall survival (OS),
disease-free survival (DFS), local recurrence-free survival
(LRFS), and distant metastasis-free survival (DMFS) were
compared between patients who did and did not receive
adjuvant chemotherapy. Multivariate analysis was performed
to explore clinical factors significantly associated with DFS,
LRFS, and DMFS.
Results For ypT0–2N0 patients, the 5-year OS, DFS, LRFS,
and DMFS were similar between patients who did and did not
receive adjuvant chemotherapy (P>0.05). For patients with
ypT3–4N0, those who were given adjuvant chemotherapy
exhibited a higher 5-year OS than those who were not (P=
0.026), with also an extended 5-year DFS (P=0.050). Further
analysis indicated that adjuvant chemotherapy could decrease
the rates of distant metastases for ypT3–4N0 patients with no
impact on local control. In multivariable analysis, both the
final pathological stage and adjuvant chemotherapy were
independent predictors of DMFS for the whole group. When
stratified by pathological stage, adjuvant chemotherapy was
still significantly associated with DMFS in the ypT3–4
stratum.
Conclusions Adjuvant chemotherapy may not improve sur-
vival for ypT0–2N0 patients. However, it may be clinically
meaningful for ypT3–4N0 patients by decreasing rates of
distant metastases. Further randomized controlled clinical tri-
als are needed to address this problem.
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Introduction
Neoadjuvant chemoradiation (CRT) followed by radical re-
section is now recommended for locally advanced rectal can-
cer [1], which brings meaningful tumor shrinking, down stag-
ing, improved local control, and increased probability of
sphincter-sparing surgery [2–5]. However, the degree of re-
sponse to CRT, with its clinical significance in predicting the
long-term outcome, varied among patients [6]. Patients who
exhibited favorable response (ypT0–2N0) were reported to
achieve excellent survival regardless of receiving adjuvant
chemotherapy or not. Postoperative adjuvant chemotherapy,
though typically recommended for all by NCCN guidelines,
seemed to contribute little to improve the survival for these
patients [6–10].
Currently, the delivery of adjuvant chemotherapy for rectal
cancer patients undergoing chemoradiation is not evidence
based [11]. Several studies have questioned the need of adju-
vant chemotherapy for ypN0 patients, especially for those
with ypT0–2 [8–10, 12]. However, it is still a controversial
problem [8–10, 12–14]. The purpose of this study was to re-
evaluate the role of adjuvant chemotherapy in patients with
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Table 1 Patient demographics,
baseline tumor characteristics,
type of surgery, and pathological
outcome




therapy, Hb hemoglobin, CEA
carcinoembryonic antigen, AV
anal verge
Variable Adjuvant-chemo group No adjuvant-chemo group P value
Age, year – – <0.001
Median 54 (15–80) 62 (39–77) –
Gender – – 0.552
Male 87 32 –
Female 28 13 –
Hb, g/L – – 0.575
Average 129 (78–170) 126 (76–160) –
CEA, μg/mL – – 0.081
Median 4.95 (0.20–157.50) 3.33 (0.54–249.60) –
Location of tumor, from AV – – 1.000
≥7.0 cm 20 (17.4 %) 7 (15.6 %) –
<7.0 cm 95 (82.6 %) 38 (84.4 %) –
Clinical T stage – – 1.000
T1 2 (1.7 %) 0 (0.0 %) –
T2 3 (2.6 %) 1 (2.2 %) –
T3 46 (40.0 %) 18 (40.0 %) –
T4 (T4a and T4b) 64 (55.7 %) 26 (57.8 %) –
Clinical N stage – – 0.612
N0 41 (35.7 %) 20 (44.4 %) –
N1 30 (26.1 %) 10 (22.2 %) –
N2 44 (38.2 %) 15 (23.4 %) –
Clinical stage – – 0.366
II 41 (35.7 %) 20 (44.4 %) –
III 74 (64.3 %) 25 (55.6 %) –
Tumor grade – – 0.743
G1 9 (7.8 %) 4 (8.9 %) –
G2 87 (75.7 %) 36 (80.0 %) –
G3 19 (16.5 %) 5 (11.1 %) –
Concurrent chemotherapy – – 0.011
Folfox6 20 (17.4 %) 17 (37.8 %) –
Xelox 95 (82.6 %) 28 (62.2 %) –
Interval, day – – 0.588
Median 42 44 –
Type of surgery – – 0.734
Mile’s 56 (48.7 %) 20 (48.9 %) –
Dixon 58 (50.4 %) 22 (48.9 %) –
Hartmann 1 (0.9 %) 1 (0.2 %) –
Retrieved lymph nodes
Median 8 7 0.234
ypT stage – – 0.603
ypT0 39 (33.9 %) 13 (28.9 %) –
ypT1 2 (1.7 %) 3 (6.7 %) –
ypT2 24 (20.9 %) 10 (22.2 %) –
ypT3 37 (34.8 %) 16 (35.6 %) –
ypT4a 10 (8.7 %) 3 (6.7 %) –
Follow-up, months – – 0.710
Median 47 41 –
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ypN0. We explored some clinical factors in predicting the
prognosis for patients in this subgroup.
Materials and methods
Ethics statement
This research was approved by the Ethics Committee of Sun
Yat-sen University Cancer Center, and the written informed
consent was obtained from every patient included in the study.
Patients
We conducted a retrospective study of 237 patients who had
undergone CRT followed by surgery at the cancer center of
Sun Yat-sen University between March 2003 and November
2010. All the patients had locally advanced rectal cancer as
shown by biopsy. There were 27 patients excluded for con-
current distant metastasis, concurrent malignancy, or prior
history of radiotherapy to the pelvis. Finally, 160 patients with
pathology of ypN0 were enrolled in this study.
Evaluation
Before CRT, all patients underwent staging workup, which
included endorectal ultrasound, computed tomography (CT),
magnetic resonance imaging (MRI), and chest radiography.
Endorectal ultrasound was typically recommended for pa-
tients for its accurate T staging in our cancer center. Abdom-
inal CT and chest radiography are routine examinations with
at least CT or MRI for the pelvis. Pre-CRT Serum CEA,
complete blood count, and liver function test were also
measured.
Treatment
Patients underwent a standard protocol of CRT with two
courses of concurrent chemotherapy. The prescription dose
to the whole pelvis was 46 Gy in 23 fractions over 5 weeks.
The technique of radiotherapy was based on a three-
dimensional conformal radiotherapy treatment planning sys-
tem (PINNACLE 8) with a three-field irradiation plan being
used (8-MV photon posterior–anterior field and 15-MV pho-
ton opposed lateral beams). The clinical target volume (CTV)
included primary rectal tumor, peri-rectal tissues, presacral
lymph nodes, internal iliac lymph nodes, and obturator lymph
nodes. The superior border of the CTV was the bottom of L5,
and the inferior border was 2.5–3 cm distal to the tumor. The
anterior border was the posterior margin of the bladder or
uterus, and the posterior border was the anterior margin of
the sacrum. PTV is defined as CTV+8∼10 mm.
The regimens of concurrent chemotherapy were Folfox6
and Xelox. There were 37 patients who were treated with
Table 2 OS and DFS for patients with ypT0–4N0
Group Adjuvant-chemo group No adjuvant-chemo group P value
3-year 5-year 3-year 5-year
OS 93.6 % 87.0 % 90.5 % 70.6 % 0.052
DFS 91.7 % 85.5 % 76.2 % 67.4 % 0.059
Adjuvant-chemo adjuvant chemotherapy, DFS disease-free survival, OS
overall survival
Fig. 1 OS for the ypT0–4N0 patients stratified by treatment with adju-
vant chemotherapy. No significant difference was found in OS between
adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0–
4N0 patients (P=0.052)
Fig. 2 DFS for the ypT0–4N0 patients stratified by treatment with
adjuvant chemotherapy. No significant difference was found in DFS
between adjuvant-chemotherapy and no adjuvant-chemotherapy groups
for ypT0–4N0 patients (P=0.059)
Int J Colorectal Dis (2014) 29:529–538 531
chemotherapy of Folfox6 (oxaliplatin 85 mg/m2 day 1 +
leucovorin 400 mg/m2 day 1 + 5-FU 400 mg/m2 iv day 1,
then 2,400 mg/m2 civ 46–48 h), while the other 123
patients received Xelox (oxaliplatin 100 mg/m2 day 1 +
capecitabine 1,000 mg/m2 bid, po, days 1–14).
At a median of 43 days (range, 20–73) after the completion
of chemoradiotherapy, radical surgery for rectal cancer was
implemented. All the operations were performed according to
the TME-principles by colorectal surgeons, and the methods
included low anterior resection, abdominoperineal resection,
and Hartmann. Negative circumferential resection margin
proved by pathology was achieved by all the patients in this
study.
Adjuvant chemotherapy were administrated in 115 pa-
tients with the regimens of Folfox6 (oxaliplatin 85 mg/m2
day 1 + leucovorin 400 mg/m2 day 1 + 5-FU 400 mg/m2
iv day 1, then 2,400 mg/m2 civ 46–48 h), Xelox
(oxaliplatin 130 mg/m2 day 1 + capecitabine 1,000 mg/m2
bid, po, days 1–14), and single agent capecitabine (capecit-
abine 1,250 mg/m2 bid, po, days 1–14). The median month
of adjuvant chemotherapy was 4 (range, 2–7.5). The other
45 patients were not scheduled with adjuvant chemotherapy
due to various reasons such as, severe postoperative com-
plications, poor performance status, or refusal due to elder
age.
Pathological classification
Pathological tumor staging of the resected specimen was
performed by experienced pathologists. The operative
specimens of 160 patients were restaged by two indepen-
dent pathologists according to the American Joint Com-
mittee on Cancer (AJCC) 7th edition staging system. If
their stagings were inconsistent, then a third pathologist
was needed to perform the task. All the specimens were
carefully dissected by the pathologists to achieve all the
potential lymph nodes, and the median of retrieved lymph
nodes was 8 (range, 3–37).
Toxicity assessment for neoadjuvant chemoradiation
and adjuvant chemotherapy
Therapy-related adverse events were defined as complications
that occurred during treatment, which were graded by using
the Cancer Institute Common Terminology Criteria for Ad-
verse Events version 3.0. Severe adverse events were defined
as any grade ≥3 toxicity. Adverse events were recorded for
each patient treated in our cancer center and were documented
in our colonrectal database.
Follow-up
The follow-up policy was every 3 months for the first 2 years
after surgery and every 6 months thereafter. However, during
the period of postoperative adjuvant chemotherapy, the
follow-up was delayed until the completion of all treatments.
Evaluations included complete blood count, liver function
test, CEA, CA19-9, and physical examination during each
visit. Chest radiography, CT scanning of the abdomen and
pelvis, and colonoscopy were conducted every 6 months.
Every follow-up for each patient was recorded in our database.
In this study, the median follow-up period for all patients was
46 months (range, 18–101).
Statistical analysis
All statistical analyses were performed by SPSS software,
version 17.0. Categorical variables were analyzed by using
the chi-square test or Fisher’s exact test. Continuous variables
were analyzed by the Student t test or Mann–Whitney U test.
The Kaplan–Meier method was employed to compare DFS
rates and OS rates. Multivariate analysis of DFS, LRFS, and
Fig. 3 OS for the ypT0–2N0 patients stratified by treatment with adju-
vant chemotherapy. No significant difference was found in OS between
adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0–
2N0 patients (P=0.401)
Table 3 OS and DFS for patients with ypT0–2N0
Group Adjuvant-chemo group No adjuvant-chemo group P value
3-year 5-year 3-year 5-year
OS 93.7 % 93.7 % 96.2 % 83.7 % 0.401
DFS 92.2 % 85.8 % 80.4 % 73.1 % 0.359
Adjuvant-chemo adjuvant chemotherapy, DFS disease-free survival, OS
overall survival
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DMFS was performed by Cox proportional hazards regres-
sion, and the Cox proportional hazards model was performed
using a forward conditional selection of variables. Variables
with Pvalue<0.2 were entered into a Cox model. P<0.05 was
considered to be statistically significant.
Results
Clinical characteristics
There were 160 patients who completed CRT and were node-
negative on the final pathology enrolled in our study. Among
them, 115 patents received postoperative adjuvant chemother-
apy, while 45 patents did not. Compared to patients who
received adjuvant chemotherapy, those who did not were
significantly older (P<0.001) and more likely to receive the
concurrent chemotherapy of Folfox6 (P=0.011). Other vari-
ables such as gender, Hb, CEA, location of tumor, clinical
tumor stage, clinical T stage, clinical N stage, tumor grade,
interval between completion of chemoradiotherapy and sur-
gery, type of surgery, number of retrieved lymph nodes, ypT
stage, and follow-up were similar between two groups
(Table 1).
Survival analysis
For the whole group, the median follow-up was 46 months
and the 5-year OS and DFS in the adjuvant and non-adjuvant
chemotherapy groups were 87.0, 85.5 % and 70.6, 67.4 %,
respectively (Table 2; Figs. 1 and 2). Further analysis showed
that the 5-year OS and DFS were similar between patients
who did and did not receive adjuvant chemotherapy in the
ypT0–2N0 subgroup (Table 3; Figs. 3 and 4). However, for
patients with ypT3–4N0, receiving adjuvant chemotherapy
had the tendency to acquire higher OS and DFS than those
who did not (Table 4; Figs. 5 and 6).
Fig. 6 DFS for ypT3–4N0 patients stratified by treatment with adjuvant
chemotherapy. The DFS was significantly higher in adjuvant-chemother-
apy group than that in no adjuvant-chemotherapy group for ypT3–4N0
patients (P=0.050)
Fig. 5 OS for the ypT3–4N0 patients stratified by treatment with adju-
vant chemotherapy. The OS was significantly higher in adjuvant-chemo-
therapy group than that in no adjuvant-chemotherapy group for ypT3–
4N0 patients (P=0.026)
Table 4 OS and DFS for patients with ypT3–4N0
Group Adjuvant-chemo group No adjuvant-chemo group P value
3-year 5-year 3-year 5-year
OS 93.6 % 81.1 % 82.1 % 49.3 % 0.026
DFS 88.3 % 84.8 % 71.1 % 59.2 % 0.050
Adjuvant-chemo adjuvant chemotherapy, DFS disease-free survival, OS
overall survival
Fig. 4 DFS for the ypT0–2N0 patients stratified by treatment with
adjuvant chemotherapy. No significant difference was found in DFS
between adjuvant-chemotherapy and no adjuvant-chemotherapy groups
for ypT0–2N0 patients (P=0.359)
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Recurrence analysis
During the follow-up, 25 patients recurred. Among them,
local failure occurred in eight patients, and distant failure
occurred in 17 patients. For the subgroup of ypT0–2N0, no
differences were found in both local and distant recurrences
between patients who received adjuvant chemotherapy and
those who did not (Table 5; Figs. 7 and 8). In ypT3–4N0
subgroup, though patients given no adjuvant chemotherapy
did not show increased risk of local recurrence than those who
were given, distant metastases rates were significant higher in
these patients (Table 6; Fig. 9).
Clinical predictors for DFS, LRFS, and DMFS
In multivariable analysis, both the final pathological stage
and adjuvant chemotherapy were independent predictors of
DMFS for the whole group (ypT0–4N0) but with no
clinical factors found to be associated with LRFS (Table 7).
When stratified by pathological stage, no clinical factor
were found to predict that LRFS adjuvant chemotherapy
was still significantly associated with DMFS with the
adjusted HR of 0.297 (95 % CI 0.095 to 0.924, P=
0.036), in the ypT3–4 stratum (Table 8).
Toxicity of chemoradiation and adjuvant chemotherapy
During the neoadjuvant chemoradiation, the most com-
mon toxicity types observed were diarrhea, neutropenia,
and abdominal pain, and major severe adverse events
(grade ≥ 3) included diarrhea (15.0 %), enteritis
(12.6 %), and neurotoxity (5.6 %) (Table 9). However,
the most common toxicity types for adjuvant chemo-
therapy were diarrhea, hand–foot syndrome, and neutro-
penia. Severe adverse events, during the adjuvant che-
motherapy, were observed most in the toxicity types of
diarrhea (17.4 %), nausea (4.3 %), and neurotoxity
(4.3 %) (Table 10). No patents died of severe adverse
events.






3-year 5-year 3-year 5-year
LR 4 (6.2 %) 5 (7.7 %) 2 (7.7 %) 2 (7.7 %) 1.000
SM 1 (1.5 %) 2 (3.1 %) 2 (7.7 %) 3 (11.5 %) 0.153
Adjuvant-chemoadjuvant chemotherapy, LR local recurrence, SMsystem-
ic metastases
Fig. 7 Cumulative hazard of local recurrence for ypT0–2N0 patients
stratified by treatment with adjuvant chemotherapy. No significant dif-
ference was found in cumulative hazard of local recurrence between
adjuvant-chemotherapy and no adjuvant-chemotherapy groups for
ypT0–2N0 patients (P=1.000)
Fig. 8 Cumulative hazard of systemic metastases for ypT0–2N0 patients
stratified by treatment with adjuvant chemotherapy. No significant dif-
ference was found in cumulative hazard of systemic metastases between
adjuvant-chemotherapy and no adjuvant-chemotherapy groups for ypT0–
2N0 patients (P=0.153)






3-year 5-year 3-year 5-year
LR 1 (2.0 %) 1 (2.0 %) 0 (0.0 %) 0 (0.0 %) 0.538
SM 4 (8.0 %) 6 (12.0 %) 5 (26.3 %) 6 (31.6 %) 0.026
Adjuvant-chemoadjuvant chemotherapy, LR local recurrence, SMsystem-
ic metastases
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Discussion
In our present study, for patients with ypT0–4N0, 5-year OS
and DFS in the adjuvant and no adjuvant-chemotherapy
groups were 87.0, 85.5 % and 70.6, 67.4 %, respectively, with
both the P values close to 0.050. Further subgroup analysis
showed that postoperative adjuvant chemotherapy did not
improve the survival for patients with ypT0–2N0, but for
ypT3–4N0 patients, the 5-year OS were higher in the
adjuvant-chemotherapy group than no in the adjuvant-
chemotherapy group with also a tendency for 5-year DFS;
meaning that the postoperative adjuvant chemotherapy may
be clinically beneficial for patients with ypT3–4N0.
We then explored the patterns of recurrence for the entire
group (ypT0–4N0) and subgroups (ypT0–2N0, ypT3–4N0).
The results indicated similar local recurrence rates between
patients who were given postoperative adjuvant chemothera-
py and those who were not. However, the rates of distant
metastases were found higher in no adjuvant-chemotherapy
group compared to those in adjuvant-chemotherapy group for
ypT3–4N0 patients. This was not shown in ypT0–2N0 pa-
tients; revealing that the real benefit of postoperative adjuvant
chemotherapy lay in reducing the risk of distant metastasis for
those with ypT3–4N0. To adjust other potentially measured
confounders such as age and concurrent chemotherapy, mul-
tivariate analysis was performed by Cox proportional hazards
regression. The results showed that both the final pathological
stage and adjuvant chemotherapywere independent predictors
of DMFS for the whole group (ypT0–4N0) and with no
clinical factors associated with LRFS. After stratified by path-
ological stage, adjuvant chemotherapy was still significantly
associated with DMFS in the ypT3–4N0 stratum, with pa-
tients who did not receive adjuvant chemotherapy having a
3.4-fold increased risk of distant metastasis relative to those
who did.
The contemporary management of locally advanced rectal
cancer is long-course chemoradiation followed by radical
resection. No matter what the final pathology is, a full course
of adjuvant chemotherapy is recommended. However, there is
no sufficient evidence supporting this strategy [11]. The only
clinical randomized controlled studies exploring the signifi-
cance of chemotherapy given preoperatively or postoperative-
ly for rectal cancer patients receiving preoperative radiother-
apy failed to demonstrate that the postoperative adjuvant
chemotherapy could significantly improve the OS and DFS
[4]. The study group took a retrospective analysis subsequent-
ly with their results revealing that postoperative adjuvant
chemotherapy could improve the 5-year OS and DFS for
ypT0–2 patients but not for those with ypT3–4. [13] Their
exploratory analysis suggested that same prognostic factor
may drive both tumor sensitivity for primary treatment and
long-term clinical benefit from further adjuvant chemothera-
py. Thus, patients with good response to chemoradiation or
radiotherapy may benefit from the later adjuvant chemother-
apy, but they may devote all their attention to treatment
response, failing to consider the prognosis of patients in the
management of adjuvant chemotherapy. Patients with a good
response to chemoradiation (ypT0–2N0) have been reported
Fig. 9 Cumulative hazard of systemic metastases for ypT3–4N0 patients
stratified by treatment with adjuvant chemotherapy. The cumulative
hazard of systemic metastases was significantly higher in no adjuvant-
chemotherapy group than that in adjuvant-chemotherapy group for
ypT3–4N0 patients (P=0.026)
Table 7 Multivariate analyses of DFS, LRFS, and DMFS for ypT0–4 patients
Variable DFS LRFS DMFS
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
yp T stage
ypT0–2 vs ypT3–4 NA 5.264 (0.648–42.791) 0.120 0.267 (0.094–0.761) 0.014
Adjuvant-chemo
yes vs no 0.476 (0.216–1.050) 0.066 NA 0.294 (0.113–0.766) 0.012
DFS disease-free survival, LRFS local recurrence-free survival, DMFS distant metastasis-free survival, NA not available, CI confidence interval, HR
hazard ratio, Adjuvant-chemoAdjuvant chemotherapy
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to acquire a favorable outcome regardless of receiving adju-
vant chemotherapy or not. The contribution of adjuvant che-
motherapy, though seemly effective, did little in improving the
survival for ypT0–2N0 patients [8–10, 12]. Patients with
ypT3–4 or N+ may need adjuvant chemotherapy for their
increased risks of recurrence. Besides, the subsequent study
was based only on the pathological T staging in the subgroup
analysis and ignoring the pathological N stage, which was
considered as a significant prognostic factor for rectal cancer
patients who received CRT [15–18].
The role of adjuvant chemotherapy for ypN0 patients was
first questioned by Fietkau et al [19]. In his study, disease-free
survival for patients without lymph node metastases (ypN0)
was excellent, independent of whether they had received
postoperative chemotherapy. Similar results were as reported
by Kiran ea al. [12], whose study included 128 rectal cancer
cases with ypT0–4N0. Among these, 58 cases received adju-
vant chemotherapy and 70 did not. The rates of local recur-
rence (P=1.00), DFS (P=0.41), and OS (P=0.52) were com-
parable between two groups. Therefore, the author put for-
ward a strong challenge to routinely administer adjuvant che-
motherapy for postoperative rectal cancer patients with ypN0.
Further subgroup analysis of ypN0was performed by Huh JW
et al. [9], who found that adjuvant chemotherapy did not
significantly improve survival for ypT0–2N0 patients. They
did not present the results for those with ypT3–4N0. The
recurrence rates for ypN0 patients were analyzed by
Govindarajan et al. [8], with the results of ypT0N0 2.7 %,
ypT1–2N0 12.3%, and ypT3–4N0 24.2%. Though the 5-year
DFS were comparable between patients receiving adjuvant
chemotherapy and those who did not in subgroups of
ypT0N0, ypT1–2N0, and ypT3–4N0, multivariable analysis
showed pathological staging as the factor that was most
strongly associated variable with recurrence (ypT3–4 vs
ypT1–2, P<0.0001) and that the value of adjuvant chemother-
apy for ypT3–4N0 may need more investigation. Our present
study showed that both the final pathological stage and adju-
vant chemotherapy were significantly associated with distant
metastasis for the whole group (ypT0–4N0) in the multivari-
able analysis. Thus, adjuvant chemotherapy, which was the
only independent predictor of DMFS in ypT3–4 stratum when
multivariable analysis of subgroups is performed, may be
especially needed for the patients with final pathology of
ypT3–4N0 to decrease the rates of distant failure.
Table 8 Multivariable analyses of DFS, LRFS, and DMFS for ypT3–4 patients
Variable DFS LRFS DMFS
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
yp T stage
ypT0–2 vs ypT3–4 NA NA NA
Adjuvant-chemo
yes vs no 0.354 (0.118–1.057) 0.063 NA 0.297 (0.095–0.924) 0.036
DFS disease-free survival, LRFS local recurrence-free survival, DMFS distant metastasis-free survival, NA not available, CI confidence interval, HR
hazard ratio. Adjuvant-chemo adjuvant chemotherapy




1∼2 3 4 5 ≥3
Abdominal distension 20 (12.5 %) 4 (2.5 %) NA NA 4 (2.5 %)
Abdominal pain 57 (35.6 %) 3 (1.9 %) 0 0 3 (1.9 %)
Nausea 40 (25 %) 6 (3.8 %) 0 0 6 (3.8 %)
Vomiting 33 (20.6 %) 5 (3.1 %) 0 0 5 (3.1 %)
Enteritis 30 (18.8 %) 18 (11.3 %) 2 (1.3 %) 0 20 (12.6 %)
Diarrhea 60 (37.5 %) 20 (12.5 %) 4 (2.5 %) 0 24 (15.0 %)
Constipation 44 (27.5 %) 5 (3.1 %) 3 (1.9 %) 0 8 (5.0 %)
Neurotoxity 34 (21.3 %) 9 (5.6 %) 0 0 9 (5.6 %)
Hand–foot syndrome 56 (35.0 %) 3 (1.9 %) NA NA 3 (1.9 %)
Hemoglobin 27 (16.9 %) 1 (0.6 %) 0 0 1 (0.6 %)
Neutrophils 73 (45.6 %) 7 (4.4 %) 0 0 7 (4.4 %)
Platelets 20 (12.5 %) 2 (1.3 %) 0 0 2 (1.3 %)
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NCCN recommends 4–6 months of postoperative adjuvant
chemotherapy for all the locally rectal cancer patients receiv-
ing CRT and with the possible considerations that neo-CRT is
a loco-regional therapy that should not, theoretically, control
the potential of distant metastasis and that the routine admin-
istration of adjuvant chemotherapy for the patients in the
seminal randomized trials, our results seemed to disfavor its
use for patients with ypT0–2N0 due to its failing in improve
survival significantly for these patients. If our conclusions
were true, adjuvant chemotherapy may be avoided in approx-
imately 47.0 % patients [6] who received CRT. This could
significantly reduce the toxicity caused by chemotherapy
[20–22]. Accordingly, we recommend selective administra-
tion of adjuvant chemotherapy for patients with high recur-
rence risks rather than those with fine prognosis needing
further randomized trials to confirm since our conclusions
were based on a small sample analysis.
Limitations such as small sample size, short follow-up, and
retrospective design were not avoided in our study. Another
major problem was the inconformity of regimens and courses
of adjuvant chemotherapy, which prevented us from doing
further analyses. We had difficulty in excluding the possibility
that no better survival was found in ypT0–2 patients receiving
adjuvant chemotherapy than those who did not. This was due
to the inadequate courses of adjuvant chemotherapy, since the
median month of adjuvant chemotherapy was four, but we
noticed that seven cases in the ypT0–2N0 subgroup, who had
developed recurrence in the adjuvant chemo-group, received
at least 4 months of adjuvant chemotherapy, accompanied by
five cases with recurrence in the no adjuvant-chemotherapy
group. This may support our hypothesis that this was due to
the adjuvant chemotherapy itself contributing little or no effect
on the survival for ypT0–2N0 patients rather than the courses
of it. It was also hard to decide whether the regimen of Xelox
could result in a better outcome than that of Folfox6 for ypT3–
4N0 patients, which may be analyzed by further subgroup
analysis, but with too few cases in each group and unbalanced
baseline characteristics between groups, it limited our ability
to reveal the possible clinically significant differences.
In conclusion, according to the results of our study and
other reports, for locally advanced rectal cancer after CRTand
surgery, there is no sufficient evidence supporting that post-
operative adjuvant chemotherapy could improve survival for
ypT0–2N0 patients. However, adjuvant chemotherapymay be
clinically meaningful for ypT3–4N0 patients by decreasing
rates of distant metastases, thus leading to a better DFS and
OS. We strongly suggest selective use of adjuvant chemother-
apy for ypN0 patients. Further randomized controlled clinical
trials are needed to address this problem.
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